Further investigations on whether Gö6976 or other newly-developed PKD inhibitors have therapeutic effects on arthritis, whether PKD inhibitors can enhance therapeutic efficacy of the currently existing arthritis treatment regimens, and whether PKD inhibitors have prophylactic and/or therapeutic effects on other experimental models of arthritis, will all be worthy of pursuing in the future. This evidence concerns the gene PRKD1 and arthritic joint disease.